Oncologist-approved cancer information from the American Society of Clinical Oncology
Printer Friendly
Download PDF

Adenoid Cystic Carcinoma

This section has been reviewed and approved by the Cancer.Net Editorial Board, 9/2013
Statistics

ON THIS PAGE:You will find information about how many people learn they have this type of cancer each year and some general survival information. Remember, survival rates depend on several factors. To see other pages in this guide, use the colored boxes on the right side of your screen, or click “Next” at the bottom

AdCC is rare. AdCC is most often diagnosed in people in their 40s to 60s, but there are known cases of pediatric (childhood) AdCC. Each year, approximately 1,200 people are diagnosed with AdCC in the United States, and about 60% are women.

The five-year survival rate is the percentage of people who survive at least five years after the cancer is detected, excluding those who die from other diseases. The five year survival rate of people with AdCC is approximately 89%. The 15-year survival rate of people with AdCC is approximately 40%. Tumor growth for AdCC is often slow, and people may live a long time with metastatic disease; however, a late recurrence (cancer that comes back after treatment) of AdCC is common and can occur many years after initial treatment.

Cancer survival statistics should be interpreted with caution. These estimates are based on data from thousands of people with this type of cancer in the United States, but the actual risk for a particular individual may differ. It is not possible to tell a person how long he or she will live with AdCC. Because survival statistics are often measured in multi-year intervals, they may not represent advances made in the treatment or diagnosis of this cancer. Learn more about understanding statistics.

Sources:  Oral Cancer Foundation and Adenoid Cystic Carcinoma Research Foundation.

Last Updated: 
Friday, February 21, 2014

© 2005-2014 American Society of Clinical Oncology (ASCO). All rights reserved worldwide.

Connect With Us: